Vitrectomy Combined With Intravitreal Dexamethasone Implant for Idiopathic Epiretinal Membrane With Macular Oedema
Launched by SHANGHAI EYE DISEASE PREVENTION AND TREATMENT CENTER · Jan 28, 2024
Trial Information
Current as of July 04, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • symptomatic patients aged 40 years or above with idiopathic stage 3-4 epiretinal membrane defined on the basis of spectral-domain optical coherence tomography classification;
- • central retinal thickness \>300 µm;
- • cystoid oedema within a 1 mm diameter range with the macular fovea as the center;
- • ocular axial length less than 25.00 mm.
- Exclusion Criteria:
- • concomitant or previous macular diseases that may hinder visual improvement other than epiretinal membrane (e.g., age-associated macular degeneration, retinal vein occlusion, or diabetic macular oedema);
- • previous vitreoretinal surgery or intravitreal injection history;
- • history of glaucoma or optic neuropathy of any kind;
- • patients with uncontrolled systemic diseases or infectious diseases;
- • patients who took medicines that may have ocular side effects, such as glucocorticoid or hydroxychloroquine.
About Shanghai Eye Disease Prevention And Treatment Center
The Shanghai Eye Disease Prevention and Treatment Center is a leading clinical research organization dedicated to advancing the understanding and treatment of ocular diseases. With a strong emphasis on innovation and patient-centered care, the center collaborates with various stakeholders, including academic institutions and healthcare providers, to conduct rigorous clinical trials. Its mission is to enhance eye health outcomes through evidence-based research, contributing to the global body of knowledge in ophthalmology. The center is committed to fostering a culture of excellence in clinical practices, ensuring the highest standards of safety and efficacy in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Tao Sun, Ph.D.
Study Chair
Shanghai Eye Diseases Prevention & Treatment Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported